Celcuity Inc
CELC
查看详细走势图
99.740USD
-0.180-0.18%
收盘 12/31, 16:00（美东）报价延迟15分钟
4.32B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.18%
5天
-2.80%
1月
-1.38%
6月
+647.12%
今年开始到现在
0.00%
1年
+661.96%
查看详细走势图
TradingKey Celcuity Inc股票评分
单位: USD 更新时间: 2025-12-31操作建议
Celcuity Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名111/403位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价106.44。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Celcuity Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
10
位分析师
买入
评级
106.444
目标均价
+2.31%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Celcuity Inc亮点
亮点风险
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-27.05，处于3年历史低位
机构加仓
最新机构持股39.79M股，环比增加0.74%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值189.00
活跃度降低
近期活跃度降低，过去20天平均换手率1.73
Celcuity Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Celcuity Inc简介
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
公司代码CELC
公司Celcuity Inc
CEOSullivan (Brian F)
网址https://www.celcuity.com/
常见问题
Celcuity Inc(CELC)的当前股价是多少？
Celcuity Inc(CELC)的当前股价是 99.740。
Celcuity Inc的股票代码是什么？
Celcuity Inc的股票代码是CELC。
Celcuity Inc股票的52周最高点是多少？
Celcuity Inc股票的52周最高点是112.640。
Celcuity Inc股票的52周最低点是多少？
Celcuity Inc股票的52周最低点是7.575。
Celcuity Inc的市值是多少？
Celcuity Inc的市值是4.32B。
Celcuity Inc的净利润是多少？
Celcuity Inc的净利润为-111.78M。
现在Celcuity Inc(CELC)的股票是买入、持有还是卖出？
根据分析师评级，Celcuity Inc(CELC)的总体评级为买入，目标价格为106.444。
Celcuity Inc(CELC)股票的每股收益（EPS TTM）是多少
Celcuity Inc(CELC)股票的每股收益（EPS TTM）是-3.687。
相关品种
